Mosunetuzumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Mosunetuzumab comprises 23 peer-reviewed publications across 12 journals, 2 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Lymphoma, Non-Hodgkin, and Lymphoma, B-Cell. Most recent publication: Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin Lymphoma., J Med Chem, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study.
    Westin J, Phillips TJ, Mehta A, et al. · Blood Adv · 2025
    PubMed: PMID 39908481 · NCT03677141 · Lymphoma, B-Cell
  2. Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma.
    Sharp J, Shana'ah AY, Voorhees TJ, et al. · J Natl Compr Canc Netw · 2025
    PubMed: PMID 40550489 · NCT06569680
  3. Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin Lymphoma.
    Mortensen DS, Shunatona HP, Holmberg-Douglas N, et al. · J Med Chem · 2026
    PubMed: PMID 41670385 · NCT06090539 · Lymphoma, Non-Hodgkin
  4. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.
    Lewis KL, Assouline SE, Baker R, et al. · Blood Adv · 2026
    PubMed: PMID 41643182 · NCT02500407 · Lymphoma, Non-Hodgkin
  5. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
    Budde LE, Sehn LH, Matasar M, et al. · Lancet Oncol · 2022
    PubMed: PMID 35803286 · NCT02500407 · Lymphoma, Non-Hodgkin
  6. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
    Budde LE, Olszewski AJ, Assouline S, et al. · Nat Med · 2024
    PubMed: PMID 38072960 · NCT03671018 · Lymphoma, B-Cell
  7. Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.
    Budde LE, Kamdar M, Assouline SE, et al. · Blood · 2026
    PubMed: PMID 42013019 · NCT03671018 · Lymphoma, B-Cell
  8. Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.
    Bartlett NL, Sehn LH, Assouline S, et al. · Am J Hematol · 2026
    PubMed: PMID 41862428 · NCT02500407 · Lymphoma, Non-Hodgkin

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT05171647
SUNMO
Lymphoma, Non-HodgkinObjective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP)
Up to approximately 23.8 months
Arm A: Mosun-Pola69.7 percentage of participants
Arm B: R-GemOx44.1 percentage of participants
NCT05171647
SUNMO
Lymphoma, Non-HodgkinProgression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT Scans
Up to 32 months
Arm A: Mosun-Pola11.5 months
Arm B: R-GemOx3.8 months

Publications by year

2022–2026: 23 publications.

2022
2
2023
3
2024
7
2025
7
2026
4

Publications by indication

Lymphoma, Non-Hodgkin (18)

  • Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin Lymphoma.
    J Med Chem · 2026 · PMID 41670385 · NCT06090539
  • Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.
    Blood Adv · 2026 · PMID 41643182 · NCT02500407
  • Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.
    Am J Hematol · 2026 · PMID 41862428 · NCT02500407
  • Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.
    Blood · 2025 · PMID 39447094 · NCT02500407
  • Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma.
    Clin Transl Sci · 2025 · PMID 40279333 · NCT02500407

Lymphoma, B-Cell (4)

  • Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.
    Blood · 2026 · PMID 42013019 · NCT03671018
  • Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study.
    Blood Adv · 2025 · PMID 39908481 · NCT03677141
  • Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
    Nat Med · 2024 · PMID 38072960 · NCT03671018
  • Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.
    Blood Adv · 2023 · PMID 37581593 · NCT03677141

Publications by journal

Trial-results highlights

The SUNMO study (NCT05171647) investigated Mosunetuzumab in participants diagnosed with Non-Hodgkin Lymphoma. One of the key primary outcomes reported in this study was the objective response rate (ORR), which was determined by an independent review facility (IRF) using Lugano Response Criteria 2014 based on Positron Emission Tomography-computed Tomography (PET-CT) or CT scans. In the interim analysis population, assessed for up to approximately 23.8 months, the Mosun-Pola arm reported an ORR in 69.7 percentage of participants. The R-GemOx arm reported an ORR in 44.1 percentage of participants. Another important primary outcome measured in the SUNMO study (NCT05171647) was progression-free survival (PFS). This outcome was also determined by the IRF, following Lugano Response Criteria 2014 using PET-CT or CT scans. The median PFS observed in the Mosun-Pola arm was 11.5 months. In the R-GemOx arm, the median PFS was 3.8 months. This endpoint was assessed for up to 32 months. All values presented here are sourced from primary registry reporting on ClinicalTrials.gov, and individual published papers should be consulted for comprehensive clinical context and decision-making.

All Mosunetuzumab publications (23)

2026 (4 papers)

  1. Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin Lymphoma.
    Mortensen DS, Shunatona HP, Holmberg-Douglas N, et al. · J Med Chem · 2026 · Derived
    PubMed: PMID 41670385 · NCT06090539 · Lymphoma, Non-Hodgkin
  2. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.
    Lewis KL, Assouline SE, Baker R, et al. · Blood Adv · 2026 · Derived
    PubMed: PMID 41643182 · NCT02500407 · Lymphoma, Non-Hodgkin
  3. Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.
    Budde LE, Kamdar M, Assouline SE, et al. · Blood · 2026 · Derived
    PubMed: PMID 42013019 · NCT03671018 · Lymphoma, B-Cell
  4. Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.
    Bartlett NL, Sehn LH, Assouline S, et al. · Am J Hematol · 2026 · Derived
    PubMed: PMID 41862428 · NCT02500407 · Lymphoma, Non-Hodgkin

2025 (7 papers)

  1. Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study.
    Westin J, Phillips TJ, Mehta A, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 39908481 · NCT03677141 · Lymphoma, B-Cell
  2. Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma.
    Sharp J, Shana'ah AY, Voorhees TJ, et al. · J Natl Compr Canc Netw · 2025 · Derived
    PubMed: PMID 40550489 · NCT06569680
  3. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.
    Sehn LH, Bartlett NL, Matasar MJ, et al. · Blood · 2025 · Derived
    PubMed: PMID 39447094 · NCT02500407 · Lymphoma, Non-Hodgkin
  4. Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma.
    Li J, Liao MZ, Wilkins J, et al. · Clin Transl Sci · 2025 · Derived
    PubMed: PMID 40279333 · NCT02500407 · Lymphoma, Non-Hodgkin
  5. Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma.
    Danilov AV, Kambhampati Thiruvengadam S, Linton K, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40472301 · NCT02500407 · Lymphoma, Non-Hodgkin
  6. Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas.
    Chong EA, Penuel E, Napier EB, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 39571171 · NCT02500407 · Lymphoma, Non-Hodgkin
  7. Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.
    Budde LE, Zhang H, Kim WS, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 41037766 · NCT05171647 (SUNMO) · Lymphoma, Non-Hodgkin

2024 (7 papers)

  1. Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
    Schuster SJ, Huw LY, Bolen CR, et al. · Blood · 2024 · Derived
    PubMed: PMID 38048694 · NCT02500407 · Lymphoma, Non-Hodgkin
  2. Matching-Adjusted Indirect Comparisons of Axicabtagene Ciloleucel to Mosunetuzumab for the Treatment of Relapsed/Refractory Follicular Lymphoma.
    Ray MD, Kanters S, Beygi S, et al. · Transplant Cell Ther · 2024 · Derived
    PubMed: PMID 38901633 · NCT02500407 · Lymphoma, Non-Hodgkin
  3. Automated Lugano Metabolic Response Assessment in 18F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on 18F-Fluorodeoxyglucose-Positron Emission Tomography.
    Jemaa S, Ounadjela S, Wang X, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38843483 · NCT02500407 · Lymphoma, Non-Hodgkin
  4. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
    Budde LE, Olszewski AJ, Assouline S, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 38072960 · NCT03671018 · Lymphoma, B-Cell
  5. Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
    Budde LE, Assouline S, Sehn LH, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38547425 · NCT02500407 · Lymphoma, Non-Hodgkin
  6. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
    Bosch F, Kuruvilla J, Vassilakopoulos TP, et al. · Clin Lymphoma Myeloma Leuk · 2024 · Derived
    PubMed: PMID 37981564 · NCT02500407 · Lymphoma, Non-Hodgkin
  7. Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Bender B, Li CC, Marchand M, et al. · Clin Transl Sci · 2024 · Derived
    PubMed: PMID 38808543 · NCT02500407 · Lymphoma, Non-Hodgkin

2023 (3 papers)

  1. Multiple Real-World Data Sources in a Bayesian Framework to Inform Long-Term Survival Estimates of Mosunetuzumab in Patients with Follicular Lymphoma.
    Sanchez Alvarez J, Jaber M, Blanchet Zumofen MH, et al. · Oncol Ther · 2023 · Derived
    PubMed: PMID 37851321 · NCT02500407 · Lymphoma, Non-Hodgkin
  2. Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.
    Olszewski AJ, Phillips TJ, Hoffmann MS, et al. · Blood Adv · 2023 · Derived
    PubMed: PMID 37581593 · NCT03677141 · Lymphoma, B-Cell
  3. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Bartlett NL, Assouline S, Giri P, et al. · Blood Adv · 2023 · Derived
    PubMed: PMID 37067952 · NCT02500407 · Lymphoma, Non-Hodgkin

2022 (2 papers)

  1. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
    Budde LE, Sehn LH, Matasar M, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35803286 · NCT02500407 · Lymphoma, Non-Hodgkin
  2. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
    Budde LE, Assouline S, Sehn LH, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 34914545 · NCT02500407 · Lymphoma, Non-Hodgkin

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).